Cooperative Agreement R43CA228850

Award Summary The Beckman Research Institute of the City of Hope received a $690,637 Cooperative Agreement from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop and validate a minimally invasive blood-based biomarker test for the early detection of pancreatic ductal adenocarcinoma (PDAC). The research leverages 5-methylcytosine (5MC) and 5-hydroxymethylcytosine (5HMC) modifications on circulating cell-free DNA to create a combined...

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Cereus Diagnostics Corp. $764,448 under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop and validate LUNG-FAST (Fragment Analysis, SNP, and Translocations), a rapid polymerase chain reaction (PCR)-based diagnostic test for detecting clinically actionable lung cancer mutations. The three-year project, effective August 1, 2025 through July 31, 2028, will deliver a clinical-grade...

This $471,675 project grant from the Department of Health and Human Services National Institutes of Health National Cancer Institute Cancer Detection and Diagnosis Research program (CFDA 93.394) will fund research at Oregon Health & Science University to develop a nanoparticle-based blood test to distinguish pancreatic cancer from benign pancreatic disease. The researchers will use high conductance dielectrophoresis technology to simultaneously recover different types of cancer-derived...

The National Cancer Institute (NCI), through the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $678,228 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop GLISCAN - a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The 5-year project aims to optimize, verify, and validate the GLISCAN assay, which will quantify tumor mutations (TERT C228T/C250T,...

Federal Cooperative Agreement Award Summary The Beckman Research Institute of the City of Hope received a $738,675 Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop an innovative exosome-based liquid biopsy assay for the non-invasive early detection of colorectal adenomas and cancers. Awarded on March 16, 2026, with a completion date of February 28, 2031, this five-year project addresses a critical...

This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...

Federal Project Grant Summary The National Cancer Institute awarded $528,902 to The University of Texas Southwestern Medical Center on September 12, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a five-year research project examining genomic correlates of outcome in pleuropulmonary blastoma (PPB). The project focuses on understanding how different DICER1 gene variants affect clinical prognosis, microRNA production, and tumor behavior in pediatric lung...

Federal Project Grant Award Summary Alelopharma Inc. received a $399,153 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on July 9, 2025, with a completion date of June 30, 2027. The company will develop and validate an innovative liquid biopsy diagnostic platform utilizing its proprietary AleloMax detection system to identify ALK (Anaplastic Lymphoma Kinase) gene fusion translocations in cell-free RNA from blood...

Federal Cooperative Agreement Summary Mayo Clinic received a $266,736 Cooperative Agreement awarded August 1, 2025, by the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to validate a novel liquid biopsy-based assay for monitoring high-grade gliomas. The project focuses on technical and clinical validation of a circulating tumor DNA (ctDNA) plasma test that detects amplified genomic chromosomal junctions unique to individual patients' tumors....

Federal Grant Award Summary Darwin Biosciences, Inc. received a $399,998 Project Grant award dated July 17, 2025, from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an innovative point-of-need lung cancer screening device for low-resource settings. The company is adapting its existing handheld diagnostic platform—previously developed under a $12 million Department of Defense contract for pathogen detection—to identify lung cancer...